finance.yahoo.com ·
Expect Amgens Next Quarterly Earnings
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAmgen's upcoming earnings report reflects broader trends in the healthcare sector, where biotech companies face pressure from regulatory changes and competition. The modest EPS growth and stock performance lagging the S&P 500 suggest investor caution amid macroeconomic uncertainties such as inflation and interest rate fluctuations.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Amgen Inc. (AMGN) is set to release its fiscal Q1 2026 earnings on April 30, 2026.
- Analysts expect an adjusted EPS of $4.75 for Q1 2026, down from $4.90 in the same quarter last year.
- For fiscal 2026, projected adjusted EPS is $22.18, up 1.6% from $21.84 in fiscal 2025.
- Amgen's stock has risen 27.1% over the past year, lagging behind the S&P 500's 34.6% gain.
- Analysts give a 'Moderate Buy' rating with an average price target of $357.57, indicating a potential upside of 1.6%.
Amgen's upcoming earnings report is likely to exert modest negative pressure on the healthcare sector due to expected EPS decline and investor caution. However, the impact may be overstated as Amgen is just one part of a diverse sector.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- SP500_HEALTHCAREmid
- SP500_HEALTHCAREshort